

Synthesis of mannoside probes for the study of PIMs biosynthesis


Julien PIECHOWIAK [1], Marcelo. E. GUERIN [2], Julien CAILLE [1], Estelle GALLIENNE [1]

[1] Institut de Chimie Organique et Analytique (ICOA), UMR 7311 CNRS et Université d'Orléans, France. [2] IKERBASQUE, The Basque Foundation for Science, Bilbao, Spain

julien.piechowiak@univ-orleans.fr

Mycobacterium tuberculosis is the second most deadly infectious agent in the world after COVID-19. Drug treatment require daily dosage of two to four drugs over six months, and compliance is poor. Most recently, there has been an alarming rise of multi-drug resistant and extensively drug resistant tuberculosis (TB), making discovery of new drugs crucial. Current anti-TB drugs are targeting diverse biological processes[1] but no molecules are designed to target PIMs biosynthesis. PIMs (Phosphatidyl-*myo*-Inositol Mannosides) are the precursors of two major lipoglycans implicated in host-mycobacteria interactions. According to the currently accepted model, the biosynthesis starts with the transfer by essential mannosyltransferases PimA and PimB of a mannosyl residue to the 2 and 6-position of the inositol ring of PI leading to PIM₁ and then PIM₂. The acyltransferase PatA catalyzes the transfer of a palmitoyl moiety to the 6-position of the mannose ring linked to the 2-position of inositol in PIM₁ or PIM₂, to obtain Ac₁PIM₁ or Ac₁PIM₂. [2] Docking studies of PatA gave useful information for inhibitors design. [3]

We are therefore focused on the synthesis of a panel of molecules with mannosyl scaffold with the aim to develop new PatA inhibitors. Structures present different aglycones to mimic the PI part and different groups at the 6-position of mannose mimicking the acylation tetrahedral transition state. The following step will be to study the molecule/enzyme interactions, to determine the inhibitory activities and to test the best molecules on *Mycobacterium tuberculosis*.



Bibliographic references:

- [1] Z. S. Bhat, M. A. Rather, M. Maqbool, Z. Ahmad (2018), *Biomed. Pharmacother.* (103), 1733-1747.
- [2] E. Sancho-Vaello, D. Albesa-Jové, A. Rodrigo-Unzueta, M. E. Guerin (2017), *Biochim. Biophys. Acta* (1862), 1355-1367.
- [3] M. Tersa, L. Raich, D. Albesa-Jové, B. Trastoy, J. Prandi, M. Gilleron, C. Rovira, M. E. Guerin (2018), *ACS Chem. Biol.* (13), 131-140.